Evogene Ltd. (EVGN)

Market Cap	8.39M -23.3%
Revenue (ttm)	8.02M +7.2%
Net Income	-2.75M
EPS	-0.37
Shares Out	8.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	110,053
Open	0.9700
Previous Close	0.9600
Day's Range	0.9400 - 0.9761
52-Week Range	0.9100 - 2.4200
Beta	1.18
Analysts	Strong Buy
Price Target	3.50 (+258.61%)
Earnings Date	Mar 5, 2026

About EVGN

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 117
• Stock Exchange: NASDAQ
• Ticker Symbol: EVGN
• Website: https://www.evogene.com

Financial Performance

In 2024, Evogene's revenue was $8.51 million, an increase of 50.90% compared to the previous year's $5.64 million. Losses were -$16.49 million, -30.96% less than in 2023.

Analyst Summary

According to one analyst, the rating for EVGN stock is "Strong Buy" and the 12-month stock price target is $3.5.

Price Target

$3.5

(258.61% upside)

Analyst Consensus: Strong Buy